The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung ...

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...

Fibroblastic reticular cells (FRCs) create T-cell-supportive niches within lung cancer tumors, facilitating T-cell migration, ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

The therapy, branded as Bizengri, targets the NRG1 gene, which is associated with formation and progression of several tumors. The company did not immediately respond to a Reuters request for comment ...

When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable ...

The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.

Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...